LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 1029

Search options

  1. Article: Mucosal Healing in Crohn's Disease and Ulcerative Colitis.

    Peyrin-Biroulet, Laurent

    Gastroenterology & hepatology

    2022  Volume 16, Issue 4, Page(s) 206–208

    Language English
    Publishing date 2022-01-20
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2386402-3
    ISSN 1554-7914
    ISSN 1554-7914
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6543: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 517: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Editorial: risankizumab - ready to break ceilings? author's reply.

    Fumery, Mathurin / Peyrin-Biroulet, Laurent

    Alimentary pharmacology & therapeutics

    2023  Volume 57, Issue 8, Page(s) 911

    MeSH term(s) Humans ; Antibodies, Monoclonal/therapeutic use
    Chemical Substances risankizumab (90ZX3Q3FR7) ; Antibodies, Monoclonal
    Language English
    Publishing date 2023-03-23
    Publishing country England
    Document type Editorial ; Comment
    ZDB-ID 639012-2
    ISSN 1365-2036 ; 0269-2813 ; 0953-0673
    ISSN (online) 1365-2036
    ISSN 0269-2813 ; 0953-0673
    DOI 10.1111/apt.17435
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2206: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Are all the IL-23 blockers the same in inflammatory bowel disease?

    Danese, Silvio / Peyrin-Biroulet, Laurent

    Nature reviews. Gastroenterology & hepatology

    2023  Volume 21, Issue 3, Page(s) 138–139

    MeSH term(s) Humans ; Inflammatory Bowel Diseases/drug therapy ; Interleukin-23
    Chemical Substances Interleukin-23
    Language English
    Publishing date 2023-12-28
    Publishing country England
    Document type Journal Article
    ZDB-ID 2493722-8
    ISSN 1759-5053 ; 1759-5045
    ISSN (online) 1759-5053
    ISSN 1759-5045
    DOI 10.1038/s41575-023-00889-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6020: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MG 97: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Etrasimod for the treatment of ulcerative colitis.

    Wils, Pauline / Peyrin-Biroulet, Laurent

    Immunotherapy

    2023  Volume 15, Issue 5, Page(s) 311–321

    Abstract: Sphingosine-1-phosphate (S1P) and its receptor (S1PR) are involved in the pathogenesis of multiple immune-mediated inflammatory disorders, including inflammatory bowel disease. The use of S1PR modulators represents a new therapeutic option for ulcerative ...

    Abstract Sphingosine-1-phosphate (S1P) and its receptor (S1PR) are involved in the pathogenesis of multiple immune-mediated inflammatory disorders, including inflammatory bowel disease. The use of S1PR modulators represents a new therapeutic option for ulcerative colitis patients. Etrasimod is an oral selective S1PR1, S1PR4 and S1PR5 modulator that inhibits the trafficking of lymphocytes from the lymph nodes into the blood. Recently, etrasimod has demonstrated efficacy in the phase II OASIS study and its open-label extension for the treatment of ulcerative colitis patients. This article reviews the mechanism of action of etrasimod and summarizes the available clinical efficacy and safety data regarding etrasimod, which is a promising drug in the treatment of patients with moderate to severe ulcerative colitis.
    MeSH term(s) Humans ; Colitis, Ulcerative/drug therapy ; Acetates/therapeutic use ; Indoles/therapeutic use ; Inflammatory Bowel Diseases/drug therapy
    Chemical Substances etrasimod (6WH8495MMH) ; Acetates ; Indoles
    Language English
    Publishing date 2023-02-15
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2495964-9
    ISSN 1750-7448 ; 1750-743X
    ISSN (online) 1750-7448
    ISSN 1750-743X
    DOI 10.2217/imt-2022-0255
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Review article: Externally derived control arms-An opportunity for clinical trials in inflammatory bowel disease?

    Honap, Sailish / Peyrin-Biroulet, Laurent

    Alimentary pharmacology & therapeutics

    2023  Volume 58, Issue 7, Page(s) 659–667

    Abstract: Background: One of the greatest challenges in the current IBD clinical trial landscape is, perhaps, the recruitment and retention of eligible participants. Seamless testing of promising investigational compounds is paramount to address unmet needs, but ... ...

    Abstract Background: One of the greatest challenges in the current IBD clinical trial landscape is, perhaps, the recruitment and retention of eligible participants. Seamless testing of promising investigational compounds is paramount to address unmet needs, but this is hindered by a number of barriers, particularly patient concerns of placebo assignment.
    Aims: To review the use of novel trial designs leveraging externally derived data to synthetically create control groups or augment existing ones, and to summarise the regulatory position on the use of external controls for market authorisation.
    Methods: We conducted a PubMed literature search without restriction using search terms such as 'external controls' and 'historical controls' to identify relevant articles.
    Results: External controls are increasingly being used outside the context of cancer and rare diseases, including IBD, and increasingly recognised by regulatory bodies. Such designs, particularly in earlier phase trials, can inform key nodes in drug development and permit evaluating efficacy of interventions without combating the ethical and numerical enrolment challenges described. However, the lack of randomisation and blinding subjects them to significant bias. Groups require robust statistical and computational approaches to ensure patient-level data across groups are adequately balanced.
    Conclusions: While this approach has several pitfalls, and is not robust enough to replace traditional randomised, placebo-controlled trials, it may offer a compromise to address key research questions at a more rapid pace, with fewer patients, and lower cost.
    MeSH term(s) Humans ; Clinical Trials as Topic ; Drug Development ; Inflammatory Bowel Diseases/drug therapy
    Language English
    Publishing date 2023-08-21
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 639012-2
    ISSN 1365-2036 ; 0269-2813 ; 0953-0673
    ISSN (online) 1365-2036
    ISSN 0269-2813 ; 0953-0673
    DOI 10.1111/apt.17684
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2206: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article: Are All Janus Kinase Inhibitors for Inflammatory Bowel Disease the Same?

    Honap, Sailish / Danese, Silvio / Peyrin-Biroulet, Laurent

    Gastroenterology & hepatology

    2024  Volume 19, Issue 12, Page(s) 727–738

    Abstract: Ulcerative colitis and Crohn's disease are chronic, progressive inflammatory bowel diseases (IBDs) and are without a known cure. Janus kinase (JAK) is a family of cytosolic tyrosine kinases that mediate signal transduction in response to extracellular ... ...

    Abstract Ulcerative colitis and Crohn's disease are chronic, progressive inflammatory bowel diseases (IBDs) and are without a known cure. Janus kinase (JAK) is a family of cytosolic tyrosine kinases that mediate signal transduction in response to extracellular stimuli. Abrogating the proinflammatory cytokine signaling cascades using JAK inhibitors (jakinibs) has been shown to be highly effective in the treatment of numerous inflammatory diseases, including IBD. Jakinibs currently licensed for moderate-to-severe IBD include the first-generation, nonselective tofacitinib and the second-generation JAK1-selective inhibitors filgotinib (licensed outside of the United States) and upadacitinib; several other jakinibs in the therapeutic pipeline are in various stages of clinical development. The jakinib class of small-molecule drugs share numerous commonalities such as their oral administration, nonimmunogenicity, short half-life, rapid onset of action, and the same class-wide regulatory restrictions owing to safety concerns. However, jakinibs differ on several fronts, translating into important clinical practice points for health care providers managing IBD patients. This article provides an overview of the jakinib class in IBD, examines how each drug differs in terms of pharmacology as well as efficacy and safety, and offers perspectives on challenges that remain and future opportunities.
    Language English
    Publishing date 2024-02-20
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2386402-3
    ISSN 1554-7914
    ISSN 1554-7914
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6543: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 517: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Evolution of IL-23 Blockade in Inflammatory Bowel Disease.

    Danese, Silvio / Peyrin-Biroulet, Laurent

    Journal of Crohn's & colitis

    2022  Volume 16, Issue Suppl 2, Page(s) ii1–ii2

    MeSH term(s) Cytokines ; Humans ; Inflammatory Bowel Diseases/drug therapy ; Interleukin-23
    Chemical Substances Cytokines ; Interleukin-23
    Language English
    Publishing date 2022-05-12
    Publishing country England
    Document type Research Support, Non-U.S. Gov't ; Editorial
    ZDB-ID 2390120-2
    ISSN 1876-4479 ; 1873-9946
    ISSN (online) 1876-4479
    ISSN 1873-9946
    DOI 10.1093/ecco-jcc/jjab188
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6634: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Disease Clearance is not Synonymous with Cure.

    D'Amico, Ferdinando / Peyrin-Biroulet, Laurent / Danese, Silvio

    Inflammatory bowel diseases

    2023  Volume 30, Issue 3, Page(s) 509

    MeSH term(s) Humans ; Colitis, Ulcerative ; Consensus ; Mutation
    Language English
    Publishing date 2023-10-05
    Publishing country England
    Document type Editorial ; Comment
    ZDB-ID 1340971-2
    ISSN 1536-4844 ; 1078-0998
    ISSN (online) 1536-4844
    ISSN 1078-0998
    DOI 10.1093/ibd/izad236
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4530: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Disease clearance in ulcerative colitis: Is the ultimate therapeutic target?

    D'Amico, Ferdinando / Peyrin-Biroulet, Laurent / Danese, Silvio

    United European gastroenterology journal

    2023  Volume 11, Issue 8, Page(s) 717–719

    MeSH term(s) Humans ; Colitis, Ulcerative/complications ; Colitis, Ulcerative/diagnosis ; Colitis, Ulcerative/drug therapy ; Crohn Disease/therapy ; Inflammatory Bowel Diseases
    Language English
    Publishing date 2023-07-03
    Publishing country England
    Document type Editorial
    ZDB-ID 2728585-6
    ISSN 2050-6414 ; 2050-6406
    ISSN (online) 2050-6414
    ISSN 2050-6406
    DOI 10.1002/ueg2.12436
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: The case for the prevention of fistulas in patients with perianal Crohn's disease.

    de Parades, Vincent / Fathallah, Nadia / Peyrin-Biroulet, Laurent

    Clinics and research in hepatology and gastroenterology

    2023  Volume 47, Issue 5, Page(s) 102113

    MeSH term(s) Humans ; Crohn Disease/complications ; Infliximab ; Fistula ; Treatment Outcome
    Chemical Substances Infliximab (B72HH48FLU)
    Language English
    Publishing date 2023-03-21
    Publishing country France
    Document type Editorial
    ZDB-ID 2594333-9
    ISSN 2210-741X ; 2210-7401
    ISSN (online) 2210-741X
    ISSN 2210-7401
    DOI 10.1016/j.clinre.2023.102113
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top